Business Description
Farmaceutica Remedia SA
ISIN : RORMAHACNOR2
Description
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 20.31 | |||||
| Equity-to-Asset | 0.19 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.12 | |||||
| Interest Coverage | 48.73 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.39 | |||||
| Beneish M-Score | -2.3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.3 | |||||
| 3-Year EBITDA Growth Rate | -29.2 | |||||
| 3-Year EPS without NRI Growth Rate | 32.1 | |||||
| 3-Year Book Growth Rate | -0.5 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.13 | |||||
| 9-Day RSI | 24.81 | |||||
| 14-Day RSI | 28.39 | |||||
| 6-1 Month Momentum % | -1.41 | |||||
| 12-1 Month Momentum % | 2.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.1 | |||||
| Quick Ratio | 0.93 | |||||
| Cash Ratio | 0.11 | |||||
| Days Inventory | 25.1 | |||||
| Days Sales Outstanding | 99.88 | |||||
| Days Payable | 137.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 8.09 | |||||
| Dividend Payout Ratio | 1.67 | |||||
| 3-Year Dividend Growth Rate | 35.7 | |||||
| Forward Dividend Yield % | 8.09 | |||||
| 5-Year Yield-on-Cost % | 57.06 | |||||
| 3-Year Average Share Buyback Ratio | 3.5 | |||||
| Shareholder Yield % | 7.28 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 7.19 | |||||
| Operating Margin % | 1.15 | |||||
| Net Margin % | 0.37 | |||||
| FCF Margin % | 1.66 | |||||
| ROE % | 3.88 | |||||
| ROA % | 0.8 | |||||
| ROIC % | 5.15 | |||||
| ROC (Joel Greenblatt) % | 30.36 | |||||
| ROCE % | 11.5 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 22.07 | |||||
| PE Ratio without NRI | 20.6 | |||||
| Shiller PE Ratio | 7.49 | |||||
| PEG Ratio | 0.89 | |||||
| PS Ratio | 0.08 | |||||
| PB Ratio | 0.88 | |||||
| Price-to-Tangible-Book | 0.9 | |||||
| Price-to-Free-Cash-Flow | 8.24 | |||||
| Price-to-Operating-Cash-Flow | 8.24 | |||||
| EV-to-EBIT | 3.45 | |||||
| EV-to-EBITDA | 2.29 | |||||
| EV-to-Revenue | 0.04 | |||||
| EV-to-FCF | 2.44 | |||||
| Price-to-Projected-FCF | 0.57 | |||||
| Price-to-DCF (Earnings Based) | 0.66 | |||||
| Price-to-DCF (FCF Based) | 0.71 | |||||
| Price-to-Median-PS-Value | 0.71 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.21 | |||||
| Price-to-Graham-Number | 0.91 | |||||
| Price-to-Net-Current-Asset-Value | 2.69 | |||||
| Earnings Yield (Greenblatt) % | 28.99 | |||||
| FCF Yield % | 20.14 | |||||
| Forward Rate of Return (Yacktman) % | 25.5 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Farmaceutica Remedia SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil lei) | 713.811 | ||
| EPS (TTM) (lei) | 0.028 | ||
| Beta | 0.28 | ||
| Volatility % | 17.28 | ||
| 14-Day RSI | 28.39 | ||
| 14-Day ATR (lei) | 0.03049 | ||
| 20-Day SMA (lei) | 0.6771 | ||
| 12-1 Month Momentum % | 2.94 | ||
| 52-Week Range (lei) | 0.602 - 0.818 | ||
| Shares Outstanding (Mil) | 95.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Farmaceutica Remedia SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Farmaceutica Remedia SA Stock Events
| Event | Date | Price(lei) | ||
|---|---|---|---|---|
| No Event Data | ||||
Farmaceutica Remedia SA Frequently Asked Questions
What is Farmaceutica Remedia SA(BSE:RMAH)'s stock price today?
The current price of BSE:RMAH is lei0.62. The 52 week high of BSE:RMAH is lei0.82 and 52 week low is lei0.60.
When is next earnings date of Farmaceutica Remedia SA(BSE:RMAH)?
The next earnings date of Farmaceutica Remedia SA(BSE:RMAH) is .
Does Farmaceutica Remedia SA(BSE:RMAH) pay dividends? If so, how much?
The Dividend Yield %  of Farmaceutica Remedia SA(BSE:RMAH) is 8.09% (As of Today), Highest Dividend Payout Ratio of Farmaceutica Remedia SA(BSE:RMAH) was 2.06. The lowest was 0.24. And the median was 0.61. The  Forward Dividend Yield % of Farmaceutica Remedia SA(BSE:RMAH) is 8.09%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers